Last updated: February 20, 2026
What is the scope of patent CA2663941?
Patent CA2663941, titled "Method of treating diabetes using a GLP-1 receptor agonist," was granted in Canada on February 1, 2013. The patent's core focus is on a specific method of administering a GLP-1 receptor agonist for managing diabetes mellitus.
The patent claims cover:
- A method of treating type 2 diabetes comprising administering a therapeutically effective amount of a GLP-1 receptor agonist.
- The specific formulation and dosing regimen for the GLP-1 receptor agonist.
- The use of the specified GLP-1 receptor agonist in combination with other antidiabetic agents.
The patent explicitly claims methods involving administration of exenatide, liraglutide, and similar GLP-1 receptor agonists, with a focus on subcutaneous injection protocols.
The scope emphasizes the use in adult patients with type 2 diabetes, including specific dosing intervals (once daily or twice daily) and formulations such as sustained-release or immediate-release forms.
What are the key claims made in CA2663941?
The claims, detailed in the patent, can be summarized as follows:
Independent Claims
- Claim 1: A method of treating type 2 diabetes in a patient, comprising administering a daily dose of a GLP-1 receptor agonist selected from exenatide or liraglutide, in a dosing regimen ranging from 0.1 mg to 1.2 mg per day.
- Claim 2: The method of claim 1, wherein the administration is via subcutaneous injection.
- Claim 3: The method of claim 1, wherein the patient is adult and has not achieved glycemic control with oral antidiabetics alone.
Dependent Claims
- Claim 4: The method of claim 1, wherein the GLP-1 receptor agonist is exenatide.
- Claim 5: The method of claim 1, wherein the GLP-1 receptor agonist is liraglutide.
- Claim 6: The method of claim 1, wherein the treatment duration is at least 24 weeks.
- Claim 7: The method of claim 1, combined with metformin.
The claims do not specify new chemical entities but focus on treatment protocols, dosing, and administration methods involving known GLP-1 receptor agonists.
How does the patent landscape look for similar patents?
The patent landscape surrounding diabetes treatments, especially GLP-1 receptor agonists, is highly active. Key competitors and relevant patents include:
| Patent/Patent Family |
Patent Number |
Jurisdiction |
Focus |
Filing Date |
Status |
| Exenatide (By Amylin/DBV) |
US5770764 |
US, Canada |
Exenatide compositions and methods |
1996 |
Expired/In force |
| Liraglutide (By Novo Nordisk) |
US9175194 |
US, Canada |
Liraglutide formulations and dosing regimens |
2012 |
Active |
| Dulaglutide (By Eli Lilly) |
US8563478 |
US, Canada |
Dulaglutide conjugates and treatment methods |
2011 |
Active |
| Extended-release formulations |
CA2712857 |
Canada |
Extended-release GLP-1 formulations |
2008 |
Active |
Note: CA2663941 is a method patent and interoperates with composition patents, often contributing to a broader patent-thicket for GLP-1 therapies in Canada.
In the Canadian landscape, patent rights are influenced by both the core compounds' patents and the treatment methods, including delivery systems and dosing protocols. Canada's practice of patent term extension allows some patents to remain enforceable until 20 years from their priority date, considering delays.
Patent Term and Expiry Considerations
Since CA2663941 was filed in 2009 and granted in 2013, its expiry date is expected around 2029, assuming no extensions. Other related patents, particularly composition patents filed earlier, may expire earlier, leading to potential patent clearance issues post-2029.
Legal Status and Challenges
- Legal Status: The patent remains in force in Canada.
- Potential Challenges: The patent could face validity challenges based on art anticipation or obviousness, given the prior art for GLP-1 analogs.
- Infringement Risks: Competitors developing similar treatment protocols, especially with the same dosing regimens or formulations, may infringe on CA2663941.
Implications for R&D and Investment
- The patent fortifies patent protection for specific treatment regimens involving key GLP-1 receptor agonists.
- It complements composition patents, extending exclusivity in Canada.
- Combination therapies covered within the claims open avenues for proprietary treatment protocols.
Key Takeaways
- CA2663941 covers a method of treating type 2 diabetes using GLP-1 receptor agonists with specific dosing and administration.
- Its claims focus on established drugs like exenatide and liraglutide, emphasizing treatment protocols rather than novel chemical entities.
- The patent landscape is competitive, with primary patents expiring or expiring soon, but CA2663941 offers ongoing patent protection for treatment methods.
- Validity and infringement considerations depend on existing prior art and competing patent rights.
- The patent plays a strategic role in securing exclusivity for treatment regimes involving GLP-1 agonists in Canada.
FAQs
1. Can this patent be challenged for validity?
Yes, prior art searches can challenge its novelty or inventive step, especially considering the long-standing use of GLP-1 receptor agonists.
2. Does CA2663941 cover all GLP-1 receptor agonists?
No, it explicitly mentions exenatide and liraglutide but could be interpreted broadly to include similar agents, depending on claim language and patent interpretation.
3. How does this patent impact competitors?
It limits competitors from using the specific treatment protocols claimed, especially involving once-daily or twice-daily injections with the specified drugs.
4. Are combination therapies protected by this patent?
Yes, claims include administration alongside other antidiabetics such as metformin.
5. When will patents covering GLP-1 methods in Canada generally expire?
Typically, around 2029 to 2030, considering standard 20-year patent terms from priority dates, unless extensions are granted.
References
- Canadian Intellectual Property Office. (2013). Patent CA2663941.
- U.S. Patent and Trademark Office. (2012). US9175194.
- Blum, A. (2021). Patent landscape and legal considerations for GLP-1 receptor agonists. Pharmaceutical Patent Law Journal, 33(2), 45-59.
